News coverage about NeoGenomics (NASDAQ:NEO) has trended somewhat positive on Monday, Accern reports. The research firm rates the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. NeoGenomics earned a daily sentiment score of 0.23 on Accern’s scale. Accern also gave news coverage about the medical research company an impact score of 47.7276541872155 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the media stories that may have effected Accern Sentiment’s scoring:
- Anatomic Pathology Testing Market: Latest Trends and Future Outlook by 2025 (reports.pr-inside.com)
- New York REIT, Inc. (NYRT) Downgraded by BidaskClub to Strong Sell (ismboard.com)
- HollyFrontier Corporation (NYSE:HFC) Given Overweight Rating at Barclays PLC (expressnewsline.com)
- Global In-Vitro Diagnostic Testing Services Market 2017-2022 (stl.news)
- Crown Castle International Corporation (CCI) Given Consensus Recommendation of “Buy” by Analysts (wisdomsave.com)
NeoGenomics (NASDAQ NEO) traded down 0.84% during mid-day trading on Monday, reaching $9.41. The company had a trading volume of 114,931 shares. NeoGenomics has a 52-week low of $6.90 and a 52-week high of $9.93. The stock’s market capitalization is $747.04 million. The company’s 50 day moving average is $9.13 and its 200 day moving average is $8.22.
NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings results on Tuesday, July 25th. The medical research company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.03. NeoGenomics had a negative net margin of 2.81% and a positive return on equity of 6.09%. The company had revenue of $66.09 million during the quarter, compared to analyst estimates of $62.95 million. During the same quarter in the previous year, the business earned $0.04 EPS. The firm’s revenue was up 4.7% on a year-over-year basis. Equities analysts predict that NeoGenomics will post $0.18 earnings per share for the current year.
A number of analysts have recently weighed in on NEO shares. Cantor Fitzgerald reiterated a “buy” rating and set a $11.00 price target on shares of NeoGenomics in a research report on Wednesday, April 26th. Zacks Investment Research upgraded NeoGenomics from a “sell” rating to a “hold” rating in a research report on Thursday, April 27th. BTIG Research reiterated a “buy” rating and set a $11.00 price target on shares of NeoGenomics in a research report on Sunday, May 28th. ValuEngine upgraded NeoGenomics from a “sell” rating to a “hold” rating in a research report on Friday, June 23rd. Finally, BidaskClub upgraded NeoGenomics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, July 19th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $10.40.
WARNING: This piece was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at https://stocknewstimes.com/2017/08/14/neogenomics-neo-receiving-somewhat-favorable-press-coverage-study-shows-updated-updated.html.
In related news, Director Alison L. Hannah bought 20,000 shares of NeoGenomics stock in a transaction that occurred on Thursday, July 27th. The stock was purchased at an average cost of $9.19 per share, with a total value of $183,800.00. Following the purchase, the director now owns 38,782 shares in the company, valued at $356,406.58. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Jennifer Balliet sold 3,334 shares of the company’s stock in a transaction on Friday, May 26th. The stock was sold at an average price of $7.50, for a total transaction of $25,005.00. Following the completion of the transaction, the vice president now directly owns 10,049 shares of the company’s stock, valued at $75,367.50. The disclosure for this sale can be found here. Insiders sold a total of 84,890 shares of company stock valued at $665,707 in the last three months. 12.20% of the stock is owned by company insiders.
NeoGenomics Company Profile
NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.
Receive News & Ratings for NeoGenomics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
